Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-11-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-1735PMID 19920100PMCID PMC2788123
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer.

  2009cited by this paper
• Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.

  2009cited by this paper
• Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity

  2009cited by this paper
• Trastuzumab administration associated with change in HER2 status.

  2008cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2007cited by this paper
• Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer

  2007cited by this paper
• HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.

  2006cited by this paper
• Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.

  2006cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials

  2005influential reference
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  2005cited by this paper
• Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

  2005cited by this paper
• Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.

  2003cited by this paper
• ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.

  2003cited by this paper
• Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.

  2001cited by this paper
• Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

  1999cited by this paper
• Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

  1999cited by this paper
• HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

  1997cited by this paper
• MCF-7 breast cancer cells overexpressing transfectedc-erbB-2 have anin vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivityin vivo

  1995cited by this paper
• Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

  1990cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization.

  1982cited by this paper
• The World Health Organization Histological Typing of Breast Tumors—Second Edition

  1982cited by this paper
• Nuclear structure in cancer tissues.

  1957cited by this paper
• Nuclear structure in cancer tissues.

  1957cited by this paper

• Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer.

  2026cites this paper
• Breast Cancer Brain Metastases: Current Understanding and Future Directions

  2026cites this paper
• Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy.

  2025cites this paper
• The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study

  2025cites this paper
• Challenges and Prospects in HER2-Positive Breast Cancer-Targeted Therapy.

  2025cites this paper
• Therapeutic challenges in HER2-targeted antibody therapies: trastuzumab and its ADC derivatives in breast cancer.

  2025cites this paper
• Retesting of oestrogen receptor, progesterone receptor and HER2 status of invasive carcinoma of the breast after neoadjuvant chemotherapy

  2025cites this paper
• Development and multicenter external validation of an intratumoral and peritumoral ultrasound-based radiomics model for preoperative prediction of HER2 status in IHC 2 + breast cancer

  2025cites this paper
• Prognostic significance of receptor conversion following neoadjuvant therapy in breast cancer: a systematic review & meta-analysis

  2025cites this paper
• Metastatic breast cancer through the Oncotype DX Breast Recurrence Score®: insights from a small cohort study

  2025cites this paper
• Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer.

  2025cites this paper
• Evaluating Breast Cancer Intravoxel Incoherent Motion MRI Biomarkers across Software Platforms.

  2025cites this paper
• Survival Outcomes and Recurrence Patterns of Early-Stage HER2-Positive Breast Cancer Patients on Adjuvant T-DM1 Treatment: Turkish Oncology Group (TOG) Study.

  2025cites this paper
• Metabolic Alterations driven by PFKFB3 upregulation confer Resistance to Trastuzumab in HER2-Positive Breast Cancer

  2025cites this paper
• Impact of hormone receptor and HER2 conversions on survival after neoadjuvant chemotherapy in breast cancer patients

  2025cites this paper
• Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy

  2025cites this paper
• Potentiating Antibody-Dependent Cellular Cytotoxicity in Triple-Negative Breast Cancer via the Humanized Anti-CD147 Antibody

  2025cites this paper
• Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing

  2025cites this paper
• Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy

  2025cites this paper
• Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis.

  2025cites this paper
• Trastuzumab deruxtecan in HER2 overexpressing non-small cell lung cancer (NSCLC)

  2025cites this paper
• Mechanisms of reduced efficacy of HER2-targeted therapy in HER2-low breast cancer by long-term nicotine exposure in patient-derived xenograft mouse tumor models.

  2025cites this paper
• Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA

  2025cites this paper
• Neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy for human epidermal growth factor receptor 2 positive breast cancer: a real-world retrospective single-institutional study in China

  2024influential citation
• NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

  2024cites this paper
• Antibody-lectin chimeras for glyco-immune checkpoint blockade

  2024cites this paper
• Liposome-enabled bufalin and doxorubicin combination therapy for trastuzumab-resistant breast cancer with a focus on cancer stem cells

  2024cites this paper
• A dedicated structured data set for reporting of invasive carcinoma of the breast in the setting of neoadjuvant therapy: recommendations from the International Collaboration on Cancer Reporting (ICCR)

  2024cites this paper
• Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer.

  2024cites this paper
• Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases

  2024cites this paper
• Human epidermal growth factor receptor 2 (HER2) status in breast cancer: practice points and challenges

  2024cites this paper
• Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterations

  2024cites this paper
• Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.

  2024cites this paper
• Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study

  2024cites this paper
• MRI-based vector radiomics for predicting breast cancer HER2 status and its changes after neoadjuvant therapy

  2024cites this paper
• Invasive disease-free survival and brain metastasis rates in patients treated with neoadjuvant chemotherapy with trastuzumab and pertuzumab

  2024cites this paper
• Breast biomarkers evolution between primary and distant metastasis: incidence and significance

  2024cites this paper
• Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients

  2024cites this paper
• Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer.

  2024cites this paper
• Receptor Discordance in Metastatic Breast Cancer; a review of clinical and genetic subtype alterations from primary to metastatic disease

  2024cites this paper
• Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer.

  2024cites this paper
• Racial Disparities in Pathological Complete Response Among Patients Receiving Neoadjuvant Chemotherapy for Early-Stage Breast Cancer

  2023cites this paper
• Incidence and prognostic impact of HER2‐positivity loss after dual HER2‐directed neoadjuvant therapy for HER2+ breast cancer

  2023cites this paper
• Discordance of HER2 Expression and/or Amplification on Repeat Testing.

  2023cites this paper
• Chemical technology principles for selective bioconjugation of proteins and antibodies.

  2023cites this paper
• Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study).

  2023cites this paper
• Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab.

  2023cites this paper
• Using immunohistochemistry to classify the molecular subtypes of Paget's disease of the breast

  2023cites this paper
• Genomics of ERBB2-Positive Breast Cancer in Young Women Before and After Exposure to Chemotherapy Plus Trastuzumab

  2023cites this paper
• Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment

  2023cites this paper
• MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer.

  2023cites this paper
• Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature

  2023cites this paper
• Combination of Anatomical and Biological Factors to Predict Disease-Free Survival in Breast Cancer

  2023cites this paper
• Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study.

  2023cites this paper
• Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases

  2023cites this paper
• Discordance of HER2-Low between Primary Tumors and Matched Distant Metastases in Breast Cancer

  2023cites this paper
• HER2-low expression in patients with advanced or metastatic solid tumors.

  2023cites this paper
• PET receptor imaging in breast cancer

  2023cites this paper
• Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report

  2023cites this paper
• Pre- and Post-Neoadjuvant Clinicopathological Parameters Can Help in the Prognosis and the Prediction of Response in HER2+ and Triple Negative Breast Cancer

  2023cites this paper
• Clinical significance and prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients

  2023cites this paper
• The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

  2023cites this paper
• Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)

  2023cites this paper
• Treatment of HER2+ breast cancer: a retrospective of disease prognosis with loss of HER2 amplification on residual disease after neoadjuvant treatment in a community hospital setting.

  2023cites this paper
• Relationship between the change in tumour-infiltrating lymphocyte level and residual tumour after neoadjuvant chemotherapy in patients with locally advanced breast cancer

  2023cites this paper
• Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy

  2023cites this paper
• Receptor Status after Neoadjuvant Therapy of Breast Cancer: Significance and Implications

  2022cites this paper
• Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report

  2022cites this paper
• HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment

  2022cites this paper
• Management of HER2-Positive Early Breast Cancer in Italy: A Maze Presenting Opportunities and Challenges

  2022cites this paper
• HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment

  2022cites this paper
• An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.

  2022cites this paper
• Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

  2022cites this paper
• Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives

  2022cites this paper
• Overcoming Resistance to Anti-nectin-4 Antibody-Drug Conjugate.

  2022cites this paper
• Hormone Receptor and HER2 Status Switch in Non-pCR Breast Cancer Specimens after Neoadjuvant Therapy

  2022cites this paper
• The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review

  2022cites this paper
• Discordance in receptor status between primary and metastatic breast cancer and overall survival: A single-center analysis.

  2022cites this paper
• Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.

  2022cites this paper
• Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy

  2022cites this paper
• Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances

  2022cites this paper
• Synthesis, In Vitro and in Cell Study of a New Spirooxindoles-Based N-Alkylated Maleimides Targeting HER2/3 Signaling Pathway

  2022cites this paper
• Resistance to Trastuzumab

  2022cites this paper
• Impact of hormone receptor, HER2, and Ki-67 status conversions on survival after neoadjuvant chemotherapy in breast cancer patients: a retrospective study

  2022cites this paper
• Tratamiento neoadyuvante en el cáncer de mama. El papel del patólogo

  2022cites this paper
• Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE

  2022cites this paper
• Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

  2022cites this paper
• The prognostic effect of HER2 heterogeneity and YAP1 expression in HER2 positive breast cancer patients: a retrospective study.

  2022cites this paper
• Anti-HER2 therapy in metastatic breast cancer: many choices and future directions

  2022cites this paper
• Cross-Resistance Among Sequential Cancer Therapeutics: An Emerging Issue

  2022cites this paper
• Breast cancer: molecular mechanisms of underlying resistance and therapeutic approaches.

  2022cites this paper
• Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients

  2021cites this paper
• Engineering an anti-HER2 biparatopic antibody with a multimodal mechanism of action

  2021cites this paper
• Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues.

  2021cites this paper
• Targeting HER2 heterogeneity in breast cancer.

  2021cites this paper
• Clinicopathologic factors affecting discrepancies in HER2 overexpression between core needle biopsy and surgical biopsy in breast cancer patients according to neoadjuvant treatment or not

  2021cites this paper
• Cellular dormancy in minimal residual disease following targeted therapy

  2021cites this paper
• Pathology after neoadjuvant treatment – How to assess residual disease

  2021cites this paper
• Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer

  2021cites this paper
• Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer.

  2021cites this paper